Current Treatment Options in Oncology

, Volume 3, Issue 5, pp 369–373 | Cite as

primary pericardial mesothelioma

  • Neyyir Tuncay Eren
  • A. Ruchan Akar

Opinion statement

Pericardial mesothelioma is a rare cancer for which treatment options are limited. Operative intervention in pericardial mesothelioma is primarily for effusion control, for cytoreduction before multimodal therapy, or to deliver and monitor innovative intrapericardial therapies. Misdiagnosis is common. Early detection of the disease is the only hope for survival. Echocardiography, pathologic examination of pericardial fluid and pericardial biopsy, Gallium-67 scintigraph, Ber-EP4 antibody, and immunohistochemical procedures can be used. Magnetic resonance imaging is emerging as the best modality for demonstrating the nature and extent of the constrictive process, and the infiltration to the cardiac wall and great vessels. Failure of surgical techniques is usually associated with mesothelioma with entrapped heart, a large solid tumor mass, and a long history of pericardial effusion. If the tumor is localized, resection is the only hope for this rare, but lethal, entity. No single treatment modality is efficient by itself. The exact role of intracavitary chemotherapy or irradiation remains to be defined. Preliminary clinical application of photodynamic therapy and attempts at inhibiting the effects of growth factors, such as vascular endothelial growth factor and platelet-derived growth factor, and vaccine treatments are being explored. Adenoviral molecular chemotherapy recently completed phase I testing. Clinical trials for pleural mesothelioma remain important as clinicians seek to improve the outcome for patients with pericardial mesothelioma. Early diagnosis and multidisciplinary patient care is essential for improved surgical outcome. In the future, combined therapeutic strategies involving radical surgery, radiotherapy, adjuvant chemotherapy, and immunomodulation may have a role in the treatment of pericardial mesotheliomas.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pass HI, Robinson BW, Testa JR, Carbone M: Emerging translational therapies for mesothelioma. Chest 1999, 116:455S-460S.PubMedCrossRefGoogle Scholar
  2. 2.
    Krismann M, Muller KM: [Malignant mesothelioma of the pleura, pericardium and peritoneum, 1: etiology, pathogenesis, pathology. Chirurg 2000, 71: 877–886.PubMedCrossRefGoogle Scholar
  3. 3.
    Kralstein J, Frishman W: Malignant pericardial diseases: diagnosis and treatment. Am Heart J 1987, 113: 785–790.PubMedCrossRefGoogle Scholar
  4. 4.
    Warren WH: The clinical manifestations and diagnosis of mesothelioma. In Mesothelioma: Diagnosis and Management. Edited by Kittle CF. Chicago: Year Book; 1987:31.Google Scholar
  5. 5.
    Van De Water JM, Allen WA: Pericardial mesothelioma. Ann Thorac Surg 1967, 3:162–165.CrossRefGoogle Scholar
  6. 6.
    Quinn DW, Qureshi F, Mitchell IM: Pericardial mesothelioma: the diagnostic dilemma of misleading images. Ann Thorac Surg 2000, 69:1926–1927.PubMedCrossRefGoogle Scholar
  7. 7.
    Watanabe A, Sakata J, Kawamura H, et al.: Primary pericardial mesothelioma presenting as constrictive pericarditis: a case report. Jpn Circ J 2000, 64:385–388.PubMedCrossRefGoogle Scholar
  8. 8.
    Watanabe M, Suzuki H, Fukutome K, et al.: An autopsy case of a malignant pericardial mesothelioma in a Japanese young man. Pathol Int 1999, 49:658–662.PubMedCrossRefGoogle Scholar
  9. 9.
    Chun PK, Leeburg WT, Coggin JT, Zajtchuk R: Primary pericardial malignant epithelioid mesothelioma causing acute myocardial infarction. Chest 1980, 77:559–561.PubMedGoogle Scholar
  10. 10.
    Nambiar CA, Tareif HE, Kishore KU, et al.: Primary pericardial mesothelioma: one-year event-free survival. Am Heart J 1992, 124:802–803.PubMedCrossRefGoogle Scholar
  11. 11.
    Sane AC, Roggli VL: Curative resection of a well-differentiated papillary mesothelioma of the peri-cardium. Arch Pathol Lab Med 1995, 119:266–267.PubMedGoogle Scholar
  12. 12.
    Steinberg I: Angiocardiography in mesothelioma of the pericardium. Am J Roentgenol Radium Ther Nucl Med 1972, 114: 817–821.PubMedGoogle Scholar
  13. 13.
    Thomason R, Schlegel W, Lucca M, et al.: Primary malignant mesothelioma of the pericardium: case report and literature review. Tex Heart Inst J 1994, 21: 170–174.PubMedGoogle Scholar
  14. 14.
    Dodson RF, O’Sullivan M, Corn CJ, et al.: Analysis of asbestos fiber burden in lung tissue from mesothelioma patients. Ultrastruct Pathol 1997, 21: 321–336.PubMedGoogle Scholar
  15. 15.
    Antman KH, Corson JM, Li FP, et al.: Malignant mesothelioma following radiation exposure. J Clin Oncol 1983, 1:695–700.PubMedGoogle Scholar
  16. 16.
    Velissaris TJ, Tang AT, Millward-Sadler GH, et al.: Pericardial mesothelioma following mantle field radio-therapy. J Cardiovasc Surg (Torino) 2001, 42:425–427.Google Scholar
  17. 17.
    Maher EA, Shepherd FA, Todd TJ: Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 1996, 112: 637–643.Google Scholar
  18. 18.
    Fizazi K, John WJ, Vogelzang NJ: The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Semin Oncol 2002, 29:77–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Rubins JB, Greatens T, Kratzke RA, et al.: Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 1998, 157:1616–1622.PubMedGoogle Scholar
  20. 20.
    Carbone M, Rizzo P, Pass H: Simian virus 40: the link with human malignant mesothelioma is well established. Anticancer Res 2000, 20:875–877.PubMedGoogle Scholar
  21. 21.
    Shivapurkar N, Wiethege T, Wistuba II, et al.: Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem 1999, 76:181–188.PubMedCrossRefGoogle Scholar
  22. 22.
    Carbone M, Fisher S, Powers A, et al.: New molecular and epidemiological issues in mesothelioma: role of SV40. J Cell Physiol 1999, 180:167–172.PubMedCrossRefGoogle Scholar
  23. 23.
    Hubner R, Van ME: Reappraisal of the strong association between simian virus 40 and human malignant mesothelioma of the pleura [Belgium]. Cancer Causes Control 2002, 13:121–129.PubMedCrossRefGoogle Scholar
  24. 24.
    Imperiale MJ, Pass HI, Sanda MG: Prospects for an SV40 vaccine. Semin Cancer Biol 2001, 11: 81–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Catalano A, Romano M, Martinotti S, Procopio A: Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene 2002, 21: 2896–2900.PubMedCrossRefGoogle Scholar
  26. 26.
    Nowak AK, Lake RA, Kindler HL, Robinson BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002, 29:82–96.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Neyyir Tuncay Eren
    • 1
  • A. Ruchan Akar
  1. 1.Heart CenterAnkara University Faculty of MedicineDikimevi AnkaraTurkey

Personalised recommendations